Best-in-Class FcRn Reagents From Immunitrack
The efficacy of antibody-based therapeutics depends largely on the circulating antibody half-life, and this is influenced by the interaction between the antibody and FcRn receptors. Conjugation of antibody-based and other biotherapeutics to the FcRn takes advantage of FcRn’s role in immunoglobulin turnover and this can be exploited to rescue the conjugated therapeutics from early degradation.
FcRn conjugation has become one of the dominating strategies to extend the half-life of biotherapeutics, and today, our best-in-class FcRn reagents are widely used by researchers and drug developers working within biotherapeutic development and drug discovery.
Optimised Manufacturing Platform
Immunitrack has optimised the production of FcRn molecules in E. coli. For expression purposes, unpaired cysteines are mutated to serines. This does not affect the ligand binding characteristics of the resulting FcRn molecules. Molecules also contain a BirA enzyme substrate peptide (BSP tag) for biotinylation.
Immunitrack’s FcRn molecules are bound and eluted from IgG columns in a pH-dependent way to ensure that the FcRn molecules are fully active. The molecules can be supplied in enzymatically biotinylated and non-biotinylated formats. We also have the capacity to produce active FcRn in bulk quantities for customised projects (10-30 mg).
Immunitrack’s FcRn reagents are compatible for use on the following platforms: AlphaScreen (PerkinElmer), Octet (ForteBio) and Biacore, and their adaptability is further demonstrated through regular citations in peer-reviewed publications from diverse fields spanning biotherapeutics, drug discovery, cancer, autoimmune disease, and others.